Alnylam Pharma (NASDAQ: ALNY) and The Medicines Company (Nasdaq: MDCO) reported positive results from their ongoing Phase 1 clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Alnylam's (ALNY) Strong ALN-PCSsc Data at AHA Conference, FBR Capital NotesNovember 12, 2015 7:43 AM Medicines Co. (MDCO), Alnylam' (ALNY) ALN-PCSsc Data Affirm Potential bi-Annual Dose Regimen - Chardan CapitalNovember 11, 2015 12:35 PM Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at American Heart Association Meeting Confirm Potential for Bi-Annual HypercholestNovember 11, 2015 10:45 AM Medicines (MDCO)/Alnylam (ALNY) to Present Phase 1 Data on siRNA-based PCSK9 TodayNovember 11, 2015 8:23 AM Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30November 9, 2015 7:47 AM Alnylam Pharma (ALNY) Reports In-Line Q3 EPSNovember 9, 2015 7:13 AM Form 8-K ALNYLAM PHARMACEUTICALS, For: Nov 09November 9, 2015 7:11 AM